natgillin/translations-raw huggingface dataset:
Immungeniciteten af en enkelt dosis af en tidligere formulering af ProQuad, var sammenlignelig med immungeniciteten af en enkelt dosis af de individuelle vacciner, der indgik (levende skoldkoppevaccine (Oka/Merck) og MFR-vaccinen fremstillet af Merck Co., Inc.), som aktuelt anvendes rutinemæssigt til vaccination i nogle lande.
The immunogenicity of a single dose of an earlier formulation of ProQuad was comparable to the immunogenicity of a single dose of its individual component vaccines (Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.), currently used in routine vaccination in some countries.
Immunglobulin
Immune globulin
Immunglobulin
Immune glogulin
Immunglobulin (IG) må ikke gives samtidigt med M-M-RVAXPRO.
Immune globulin (IG) is not to be given concomitantly with M-M-RVAXPRO.
Immunglobulin A: Fortæl det til lægen, hvis dit blod ikke indeholder immunglobulin A (IgA).
Immunoglobulin A: Please tell your doctor if your blood does not have immunoglobulin A (IgA).
Immunglobulin: 100 mg/ml, mindst 98 % er IgG
Immunoglobulin: 100 mg/ml, at least 98% is IgG
Immunglobuliner er også kendt som antistoffer og findes i raske menneskers blod.
Immunoglobulins are also known as antibodies and are found in healthy people’s blood.
Immunglobuliner udskilles i mælk og kan bidrage til at beskytte den nyfødte mod patogener, der kan trænge ind via slimhinder.
Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.
Immunisering med Improvac resulterede i en midlertidig reduktion af testikelfunktionen.
Immunisation with Improvac resulted in a temporary reduction in the activity of the testicles.
Immunisering skal betragtes som et led i et komplekst kontrol-program, der retter sig mod alle vigtige hygiejniske faktorer og sundhedsfaktorer for fjerkræ.
Immunisation has to be considered as one component in a complex control program that addresses all important hygienic and health factors for poultry.
Immunisering skal foretages som intramuskulær injektion, helst i musculus deltoideus.
Immunisation should be carried out by intramuscular injection only, preferably into the deltoid muscle.
Immunisering skal udføres ved intramuskulær injektion i m. deltoideus.
Immunisation should be carried out by intramuscular injection into the deltoid muscle.
Immunisering skal udføres via intramuskulær (i.m.) injektion.
Immunisation must be carried out by intramuscular (IM) injection.
Immunitet indtræder 3 uger efter basisvaccination mod panleukopeni og leukæmi, og 4 uger efter basisvaccination mod calicivirus og rhinotracheitis virus.
Onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
Immunitet indtræder 3 uger efter første vaccination.
Onset of immunity: 3 weeks after the primary vaccination.
Immunitet indtræder: 14 dage.
Onset of immunity: 14 days
Immunitet indtræder: 21 dage efter vaccination Immunitetsvarighed: 105 dage efter vaccination
Onset of immunity: 21 days after vaccination Duration of immunity: 105 days after vaccination
Immunitet indtræder: 3 uger efter vaccination.
Onset of immunity: from 3 weeks post-vaccination.
Immunitet opnås generelt inden for 3 uger som vist i det pivotale, kliniske fase III-studie V58P4 for den voksne og ældre population.
Seroprotection is generally obtained within 3 weeks, as shown by the pivotal phase III clinical study V58P4 for the adult and elderly population.
Immuniteten indtræder 4 uger efter vaccination.
Onset of immunity has been demonstrated 4 weeks after vaccination.
Immuniteten indtræder: 2 uger efter grundvaccination
Onset of immunity: 2 weeks after the primary vaccination course
Immuniteten indtræder: 2 uger efter grundvaccination Immuniteten varer: 17 måneder efter grundvaccination
Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 17 months after the primary vaccination course
Immuniteten indtræder: 2 uger efter grundvaccination Immuniteten varer: 5 måneder efter grundvaccination
Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 5 months after the primary vaccination course
Immuniteten indtræder: 3 måneder efter vaccination.
Onset of immunity: 3 weeks after vaccination.
Immuniteten indtræder: 31 dage efter anden dosis.
Onset of immunity: 31 days after the second dose.
Immuniteten indtræder: Tre uger efter basisvaccinationsforløbet.
Onset of immunity: Three weeks after the basic vaccination course.
Immuniteten opnås efter 14 dage og varer i 6 måneder.
Immunity starts after 14 days and lasts for 6 months.
Immuniteten overføres fra soen til smågrisene gennem råmælken.
This immunity is passed onto the sow’s piglets through her colostrum.
Immuniteten overføres til avlskyllingernes afkom i en periode på 43 uger efter den sidste vaccination.
Immunity is transferred to the chicken’s offspring for a period of 43 weeks after the last vaccination.
Immuniteten varer indtil 1 år efter basisvaccination.
The duration of immunity is one year after the primary vaccination.
Immuniteten varer: 1 år efter anden dosis.
Duration of immunity: 1 year after the second dose.
Immuniteten varer: 17 måneder efter grundvaccination
Duration of immunity: 17 months after the primary vaccination course
Immuniteten varer: 6 måneder
Duration of immunity: 6 months.
Immuniteten varer: 6 måneder efter sidste (re-)vaccination.
Duration of immunity: 6 months after the last (re-)vaccination .
Immuniteten varer: 6 måneder efter sidste (re-)vaccination.
Duration of immunity: 6 months after the last (re-)vaccination.
Immuniteten varer: 6 måneder.
Duration of immunity: 6 months.
Immunitetens indtræden: 2 uger efter grundvaccination
Onset of immunity: 2 weeks after the primary vaccination course
Immunitetens indtræden: 3 uger Immunitetens varighed: 1 år
Onset of immunity: 3 weeks Duration of immunity: 1 year
Immunitetens indtræden: 4 uger efter vaccination.
Onset of immunity: 4 weeks after vaccination.
Immunitetens indtræden: 7 dage efter vaccination.
Onset of immunity: 7 days after vaccination.
Immunitetens indtræden: ILT: 4 uger,
Onset of immunity: ILT: 4 weeks,
Immunitetens indtræden: Tre uger efter basisvaccinationsforløbet.
Onset of immunity: Three weeks after the basic vaccination course.
Immunitetens længde: 17 måneder efter grundvaccination
Duration of immunity: 17 months after the primary vaccination course
Immunitetens varighed hos kvæg og får er 1 år efter basisvaccinationsprogrammet.
The duration of immunity for cattle and sheep is 1 year after primary vaccination course.
Immunitetens varighed hos kvæg og får er 1 år efter basisvaccinationsprogrammet.
The duration of immunity for cattle and sheep is 1 year after the primary vaccination course.
Immunitetens varighed hos ænder er ukendt.
The duration of immunity in ducks is unknown.
Immunitetens varighed i forhold til at reducere antallet af æg med abnorm skaldannelse er endnu ikke påvist.
The duration of immunity to reduce the number of eggs with abnormal shell formation has not yet been demonstrated
Immunitetens varighed: 1 år efter afslutning af basisvaccination.
Duration of immunity: one year after completion of the primary vaccination course.
Immunitetens varighed: 1 år.
Duration of immunity: 1 year.
Immunitetens varighed: 12 måneder efter afslutning af basisvaccinationsprogrammet.
Duration of immunity: 12 months after completion of the primary vaccination scheme
Immunitetens varighed: 12 måneder efter afslutning af basisvaccinationsprogrammet.
Duration of immunity: 12 months after completion of the primary vaccination scheme.
Immunitetens varighed: 12 måneder efter afslutning af basisvaccinationsprogrammet..
Duration of immunity: 12 months after completion of the primary vaccination scheme.
Immunitetens varighed: 12 måneder.
The duration of immunity: 12 months.
Immunitetens varighed: 21 dage efter vaccination.
Duration of immunity: 21 days after vaccination.
Immunitetens varighed: 280 dage efter afslutning af basisvaccination.
Duration of immunity: 280 days after completion of the primary vaccination course.
Immunitetens varighed: 6 måneder vaccination.
Duration of immunity: 6 months after vaccination.
Immunitetens varighed: ILT: 60 uger,
Duration of immunity: ILT: 60 weeks,
Immunitetensvarighed: 19 uger efter vaccination.
Duration of immunity: 19 weeks post-vaccination
Immunitetstest Standard
Immunity test standard
Immunitetsvarighed: 19 uger efter vaccination.
Duration of immunity: 19 weeks post-vaccination.
Immunitetsvarighed: Mindst 6 måneder.
Duration of immunity: at least 6 months
Immunitetsvarigheden hos ænder: 14 uger efter den anden injektion.
Duration of immunity in ducks: 14 weeks after the second injection.
Immunkompromitterede og gravide sundhedsmedarbejdere må ikke klargøre og administrere IMLYGIC.
Immunocompromised and pregnant healthcare professionals should not prepare and administer IMLYGIC.
Immunkompromitterede patienter og patienter med svær neutropeni blev udelukket fra kliniske studier.
Patients who were immunocompromised and patients with severe neutropenia were excluded from clinical trials.
Immunkompromitterede personer 21 dage efter
Immunocompromised subjects 21 Days After
Immunmedierede hændelser†
Immune-mediated events
Immunmodulation hos voksne, børn og unge (2-18 år) ved:
Immunomodulation in adults, children and adolescents (2-18 years) in:
Immunmodulation:
Immunomodulation:
Immunmodulerende lægemidler, herunder belimumab, kan øge risikoen for maligniteter.
Immunomodulatory medicinal products, including belimumab, may increase the risk of malignancy.
Immunoalle
allergic
Immunoalle
infarction
Immunoalle
thrombocy
Immunoalle
thrombocytopen
immunoallergisk
disorders
immunoallergisk
Thrombocy
Immunobehandling som supplerende behandling til kirurgi og strålebehandling hos katte med fibrosarkom (2-5 cm i diameter), hvor der ikke forekommer metastase eller spredning til lymfeknuder, for at nedsætte risiko for tilbagefald og for at forøge tidsintervallet til tilbagefald (lokalt forekommende eller metastase).
Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis).
ImmunoGam 312 IE/ml, injektionsvæske, opløsning
ImmunoGam 312 IU/ml solution for injection
ImmunoGam 312 IE/ml, injektionsvæske, opløsning Humant hepatitis B-immunglobulin
ImmunoGam 312 IU/ml solution for injection Human Hepatitis B Immunoglobulin
ImmunoGam 312 IE/ml, injektionsvæske, opløsning.
ImmunoGam 312 IU/ml solution for injection.
ImmunoGam er en opløsning til injektion, som indeholder det aktive stof humant hepatitis B- immunglobolin.
ImmunoGam is a solution for injection that contains the active substance human hepatitis B immunoglobulin.
ImmunoGam giver beskyttelse mod hepatitis B-virus i en kort periode og bruges til behandling af følgende:
ImmunoGam provides protection against hepatitis B virus for a short period of time and it is used to treat the following:
ImmunoGam har en eliminationshalveringstid på 3-4 uger.
ImmunoGam has an elimination half-life of 3 – 4 weeks.
ImmunoGam indeholder 0,16 g maltose i en dosis på 500 IE.
ImmunoGam contains 0.16 g of maltose in a 500 IU dose.
ImmunoGam indeholder maltose (10 % w/w).
ImmunoGam contains maltose (10%w/w).
ImmunoGam skal indgives intramuskulært.
ImmunoGam should be administered via the intramuscular route.
ImmunoGam udleveres i et type 1-glas-hætteglas med en silikoniseret brombutylgummiprop, aluminumsforsegling og flip-off-låg af plast.
ImmunoGam is supplied in a Type 1 glass vial with a siliconized bromobutyl rubber stopper, aluminum seal and plastic flip-off cap.
ImmunoGam yder "passiv" beskyttelse.
ImmunoGam provides ‘passive’ protection.
Immunogenicitet
Hypoglycaemia
Immunogenicitet / Antistof mod lægemidlet (ADA, Anti-Drug Antibodies)
Immunogenicity/ Anti-drug-antibodies (ADA)
Immunogenicitet af Menveo vs.
The comparative immunogenicity of Menveo vs.
Immunogenicitet blev målt ved (1) procentdelen af personer, der var seropositive for antistoffer mod den relevante vaccine-HPV-type og (2) den geometriske middeltiter (GMT).
Immunogenicity was measured by (1) the percentage of individuals who were seropositive for antibodies against the relevant vaccine HPV type, and (2) the Geometric Mean Titer (GMT).
Immunogenicitet efter to doser administreret med to måneders mellemrum hos børn fra 6 til 26 måneder er blevet undersøgt i tre studier, hvis resultater er opsummeret i tabel 4.
The immunogenicity after two doses administered two months apart in children 6 months to 26 months of age has been documented in three studies whose results are summarised in Table 4.
Immunogenicitet hos børn fra 6 til 11 måneder, 12 til 23 måneder og 2 til 10 år
Immunogenicity in children 6 to 11 months, 12 to 23 months and 2 to 10 years of age
Immunogenicitet hos kvinder i alderen 26 år og derover
Immunogenicity in women aged 26 years and older
Immunogenicitet hos mennesker
Immunogenicity in humans
Immunogenicitet hos spædbørn fra 2 til 6 måneder
Immunogenicity in infants 2 months to 6 months of age
Immunogenicitet hos unge (fra 11 år) og voksne
Immunogenicity in adolescent (from 11 years of age) and adults
Immunogenicitet hos unge i alderen 11-17 år og voksne ≥ 18 år
Immunogenicity in adolescents aged 11-17 years and adults aged ≥ 18 years
Immunogenicitet hos voksne
Immunogenicity in adults
Immunogenicitet og sikkerhed af IXIARO hos børn og teenagere fra et JEV-endemisk land
Immunogenicity and safety of IXIARO in children and adolescents from a JEV-endemic country
Immunogenicitet og sikkerhed hos børn og teenagere fra ikke-endemiske lande
Immunogenicity and safety in children and adolescents from non-endemic countries
Immunogeniciteten 21 dage efter hver halve dosis (0,25 ml) HUMENZA var som følger mht. seroprotektionsraten, serokonversionsraten og serokonversionsfaktoren ved anvendelse af HI- metoden:
The immunogenicity 21 days after each half-dose (0.25 ml) of HUMENZA in term of the seroprotection rate, the seroconversion rate and the seroconversion factor, using HI method, were as follows:
Immunogeniciteten af en dosis Nimenrix er evalueret hos mere end 8.000 personer i alderen
The immunogenicity of one dose of Nimenrix has been evaluated in more than 8,000 subjects aged
Immunogeniciteten af en serie af to doser primærvaccination til spædbørn, efterfulgt af en booster- dosis når barnet bliver ca. et år, er dokumenteret i en række undersøgelser.
The immunogenicity of a two-dose primary series in infants plus a booster at about one year of age has been documented in several studies.
Immunogeniciteten af Hexacima hos børn over 24 måneder er ikke blevet undersøgt i kliniske forsøg.
The immunogenicity of Hexacima in children over 24 months of age has not been studied in clinical trials.
Immunogeniciteten af Hexyon hos børn over 24 måneder er ikke blevet undersøgt i kliniske forsøg.
The immunogenicity of Hexyon in children over 24 months of age has not been studied in clinical trials.
Immunogeniciteten af IXIARO blev evalueret i et open-label, ukontrolleret forsøg med 200 raske ældre mennesker i alderen 65-83 år, herunder forsøgspersoner med stabile underliggende tilstande som hyperkolesterolæmi, forhøjet blodtryk, kardiovæskulær sygdom eller ikke-insulinkrævende diabetes mellitus.
The immunogenicity of IXIARO was evaluated in an open-label, uncontrolled trial in 200 healthy elderly persons aged 65 to 83 years, including subjects with stable underlying conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus.
Immunogeniciteten af og sikkerheden ved efterfølgende formuleringer af vaccinen er også blevet undersøgt.
The immunogenicity and safety of subsequent formulations of the vaccine have also been examined in studies.
Immunogeniciteten af Synflorix efter et primært vaccinationsprogram med 2 eller 3 doser til børn under 6 måneder er blevet vurderet i et klinisk studie.
The immunogenicity of Synflorix following a 2-dose or 3-dose primary vaccination schedule in subjects less than 6 months of age was evaluated in a clinical study.
Immunogeniciteten af Synflorix hos meget præmature spædbørn (født i 27.-30. svangerskabsuge) (n = 42), hos præmature spædbørn (født i 31.-36. svangerskabsuge) (n = 82) og spædbørn født ved terminen (født efter 36. svangerskabsuge) (n = 132) blev vurderet efter et primært program med 3 doser ved 2, 4, 6 måneders alderen.
Immunogenicity of Synflorix in very preterm (gestation period of 27-30 weeks) (N=42), preterm (gestation period of 31-36 weeks) (N=82) and full term (gestation period > 36 weeks) (N=132) infants was evaluated following a 3 dose primary vaccination course at 2, 4, 6 months of age.
Immunogeniciteten af vaccine med A/Vietnam/1203/2004-stammen er vurderet i tre kliniske forsøg med voksne på 18-59 år (N=961) og i to kliniske forsøg med personer på 60 år og derover (N=391), der blev vaccineret på dag 0 og dag 21.
The immunogenicity of the A/Vietnam/1203/2004 strain vaccine has been evaluated in three clinical studies in adults aged 18 – 59 years (N=961) and in two clinical studies in subjects aged 60 years and older (N=391) following a 0, 21 day schedule.
Immunogeniciteten af vaccinen indeholdende 7,5 µg non-adjuveret HA udvundet fra stamme A/Vietnam/1203/2004 er blevet vurderet i to kliniske studier med voksne på 18 – 59 år (N=312) og ældre på 60 år og derover (N=272), der fik medicinen på dag 0 og dag 21.
The immunogenicity of the vaccine containing 7.5 µg non-adjuvanted HA derived from strain A/Vietnam/1203/2004 has been evaluated in two clinical studies in adults aged 18 – 59 years (N = 312) and in older subjects aged 60 years and older (N = 272) following a 0, 21 day schedule.
Immunogeniciteten blev målt ved rSBA eller hSBA, som er biomarkører for beskyttelse mod meningokokgrupperne A, C, W-135, og Y.
Immunogenicity was measured by using rSBA or hSBA which are biomarkers for protective efficacy against meningococcal groups A, C, W-135 and Y.
Immunogeniciteten blev vurderet hos en subgruppe (n=182) af forsøgspopulationen.
Immunogenicity was assessed in a subset (n=182) of the study population.
Immunogeniciteten efter fjerde dosis (boosterdosis) ved 15-18- måneders alderen blev evalueret hos 44 meget præmature spædbørn, hos 69 præmature spædbørn og hos 127 børn født omkring terminen.
Immunogenicity following a fourth dose (booster dose) at 15 to 18 months of age was evaluated in 44 very preterm, 69 preterm and 127 full term infants.
Immunogeniciteten hos ældre mennesker (≥65 år)
Immunogenicity in elderly persons (≥65 years)
Immunogeniciteten ved anvendelse af Vaxelis til børn over 15 måneder er ikke undersøgt i kliniske studier.
The immunogenicity of Vaxelis in children over 15 months of age has not been studied in clinical trials.
Immunogenicitets- og sikkerhedsdata viser, at ProQuad kan gives til personer mellem 9 og 12 måneder under særlige omstændigheder (fx i overensstemmelse med de officielle anbefalinger, eller når tidlig beskyttelse anses for nødvendig).
Immunogenicity and safety data show that ProQuad can be administered to individuals between 9 and 12 months of age, under special circumstances (e.g., in accordance with official recommendations or when early protection is considered necessary).
Immunogenicitetsdata er vurderet hos 92 personer i vaccinegruppen i tidsintervallet 107-113 måneder (M107-M113) efter første vaccinedosis med en median- opfølgningstid på 8,9 år.
92 subjects in the vaccine group had immunogenicity data at the [M107- M113] interval after the first vaccine dose with a median follow-up of 8.9 years.
Immunogenicitetsdata fra BO22334/SABRINA og BO25341/SAWYER
Immunogenicity data from BO22334/SABRINA and
Immunogenicitetsdata fra tre langvarige kliniske undersøgelser indikerer, at ca. en tredjedel af patienterne udvikler antistoffer, bestemt ved neutraliserings-/beskyttelsesassays for mus, afhængig af eksponeringens varighed.
Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation / mouse protection assay dependent on duration of exposure.
Immunogenicitetsresultater en måned efter Menveo er angivet i tabel 4.
Immunogenicity results at one month after Menveo are summarized below in Table 4.
Immunogenicitetsresultater fra åbne kliniske afprøvninger viser at PROCOMVAX kan administreres samtidig med DTP (Difteri, Tetanus og helcelle Pertussis vaccine), OPV (Oral Poliomyelitis vaccine), IPV (inaktiveret poliomyelitis vaccine) og Merck M-M-R (levende mæslinge-parotitis-rubella vaccine) ved at anvende separate sprøjter og på forskellige injektionssteder for de injicerbare vacciner.
Immunogenicity results from open-labeled studies indicate that PROCOMVAX can be administered concomitantly with DTP (Diphtheria, Tetanus and whole cell Pertussis vaccine), OPV (Oral Poliomyelitis vaccine), IPV ( inactivated poliomyelitis vaccine) and Merck MMR (Measles, Mumps, and Rubella Virus Vaccine Live) using separate sites and syringes for injectable vaccines.
Immunogenicitetsvurderingen blev gennemført hos en undergruppe af studiepopulationen og inkluderede bestemmelse af serokonverteringsraten (SCR) defineret som en JEV-neutraliserende antistoftiter ≥1:10, andelen af forsøgspersoner, der fik en mindst fire gange stigning i antistoftiter, og den geometriske gennemsnitstiter (GMT) på Dag 56 og Måned 7 efter dosis og efter aldersgruppe.
The immunogenicity evaluation was performed in a subset of the study population and included the determination of the seroconversion rate (SCR), defined as JEV neutralizing antibody titer ≥1:10, the proportion of subjects achieving an at least four- fold increase in antibody titers and the geometric mean titer (GMT) at Day 56 and Month 7, by dose and by age group.
Immunoglobulin må ikke gives sammen med PANDEMIC INFLUENZA VACCINE H5N1 BAXTER.
Immunoglobulin is not to be given with PANDEMIC INFLUENZA VACCINE H5N1 BAXTER.
Immunokompromitterende patienter
Immunocompromised patients
Immunologiske data og data vedrørende varigheden af beskyttelse tyder dog på, at en enkelt booster-dosis bør gives, hvis der er forløbet op til 2 år siden seneste vaccination for voksne og op til 6 måneder for børn i alderen 2-6 år.
However, immunological and duration of protection data suggest that if up to 2 years have elapsed since the last vaccination for adults and up to 6 months for children aged 2-6 years a single booster dose should be given.
IMMUNOLOGISKE OPLYSNINGER
IMMUNOLOGICAL PROPERTIES
Immunomedics GmbH Otto-Rhöm-Straße 69 D-64293 Darmstadt Tyskland
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Germany
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Tyskland
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Germany
Immunosuppresiva
Immunosuppressant
Immunosuppressiva
Common
IMMUNOSUPPRESSIVA
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSIVA
Recommendations concerning co-administration
Immunosuppressiva (se pkt.
Immunosuppressants (see section 5.2)
Immunosuppressive midler (anvendes efter en organtransplantation), f.eks.: ciclosporin, everolimus, sirolimus, tacrolimus
Immunosuppressants (used after an organ transplantation) for example: ciclosporin, everolimus, sirolimus, tacrolimus
Immunprofylakse af hepatitis B
Immunoprophylaxis of Hepatitis B
Immunprofylakse af hepatitis B hos hæmodialysepatienter:
Immunoprophylaxis of hepatitis B in haemodialysed patients:
immunreaktiveringssyndrom (0,2 % over for 0,3 %), lægemiddeloverfølsomhed (0,8 % over for 1,2 %)
immune reconstitution syndrome (0.2% vs 0.3%), drug hypersensitivity (0.8% vs 1.2%)
Immunreaktiveringssyndrom forekommer, når patientens immunsystem begynder at virke igen og bekæmper eksisterende infektioner, hvilket forårsager betændelse på infektionsstedet.
Immune reconstitution syndrome happens when the patient’s immune system starts working again and fights existing infections, causing inflammation at the site of the infection.
Immunreaktiveringssyndrom, lægemiddeloverfølsomhed, overfølsomhed
immune reconstitution syndrome, drug hypersensitivity, hypersensitivity